Need an oil spill lawyer? We will fight for you!
› $150,000,000 verdict in personal injury case
The International Serious Adverse Event Consortium (SAEC) this week released its first data, offering health care professionals more insight into the genetic basis for two serious adverse drug events – Stevens Johnson Syndrome (SJS) and its most severe form, toxic epidermal necrolysis (TEN), according to Health News Digest.
The International Serious Adverse Events Consortium (SAEC) is a global, nonprofit partnership between leading pharmaceutical companies, the FDA and academic institutions. It was organized just more than a year ago. Among its goals, the consortium hopes to identify genetic markers that predict which individuals are at risk for drug-related serious adverse reactions, also known as SAEs.
Seven major pharmaceutical companies are banding together to develop genetic tests that predict which patients will have adverse side effects from drugs. The group, a nonprofit organization dubbed the International Serious Adverse Events Consortium (SAEC), will conduct two studies, one to look at drug-related liver toxicity and the other aimed at a rare drug-related skin condition called Stevens-Johnson syndrome.
![[ Beasley Allen Law Firm Logo ]](http://www.sjs-legal.com/wp-content/themes/system-unity/images/logo.png){kind=logo}